Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epristeride + silodosin
- Development stage
- Unknown
- Lead developer
- Jiangsu Lianhuan Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LH-2103 is an investigational small-molecule combination drug candidate developed by Jiangsu Lianhuan Pharmaceutical for the treatment of benign prostatic hyperplasia (BPH). It is a fixed-dose combination of epristeride, a steroid 5-alpha reductase 2 (SRD5A2) inhibitor, and silodosin, an alpha-1A adrenergic receptor (ADRA1A) antagonist. By combining these two active ingredients, LH-2103 aims to address both the hormonal and muscular components of BPH, reducing prostate volume and relieving bladder outlet obstruction. The drug is formulated as an oral capsule and has completed Phase 1 clinical trials in China.
- Other names
- epristeride/silodosinLH2103LH-2103LH 2103
02
Targets
ADRA1A (α1A)SRD5A2 (Steroid 5-alpha-reductase type II)
Beyond the preview
Go deeper on epristeride + silodosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epristeride + silodosin.